Abstract
Background: Available evidence on the prognostic role of procalcitonin levels in acute coronary syndromes (ACS) is so far controversial.Aims: To evaluate the association between procalcitonin, major cardiovascular events (MACE) and total mortality in acute coronary syndromes.Methods: Procalcitonin levels were measured in 247 patients admitted to our Intensive Cardiac Care Unit (ICCU) with ACS. Three subgroups were considered according to procalcitonin levels.Results: At Cox regression analysis, procalcitonin levels were both an unadjusted and an adjusted predictor (corrected for diagnosis and TnI) of intra-ICCU mortality and of 1-year follow-up MACE and total mortality.Conclusions: In ACS, admission procalcitonin values identify a “higher risk” group of patients for short and long-term mortality.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
